What Pre-Treatment Protocols And Patient Selection Criteria Should Aesthetic Clinics Implement When Performing Nonablative Fractional Laser Treatments On Darker Skin Types To Minimize Pih?

For Fitzpatrick IV–VI skin, the safest approach is conservative treatment preceded by melanocyte stabilization. Select patients with mild-to-moderate photodamage, rhytids, or appropriate textural concerns; defer treatment when inflammation, active infection, recent tanning, or uncontrolled pigmentary disease is present. A typical pre-treatment protocol is 4% hydroquinone plus tretinoin for 4–6 weeks, with tretinoin discontinued approximately 2 weeks before treatment, followed by low-density, low-fluence treatment with continuous epidermal cooling.

In darker skin, PIH prevention depends less on pursuing maximum laser intensity and more on controlling inflammation, heat accumulation, treatment density, and ultraviolet exposure.

Select the Right Patients Before Treating

Match the indication to nonablative fractional therapy

The strongest candidates generally have mild-to-moderate photodamage, fine rhytids, or textural irregularity that can reasonably improve with fractional dermal remodeling.

Patients should understand that nonablative fractional laser treatment usually requires multiple sessions and that pigmentary complications may occur even when the epidermis remains largely intact.

Assess baseline pigmentary risk

Document the patient’s Fitzpatrick skin type, baseline pigmentation, history of PIH, melasma, acne-related pigmentation, recent sun exposure, and response to previous procedures.

A history of prolonged or persistent PIH does not necessarily exclude treatment, but it supports a more conservative protocol, test spots, longer recovery intervals, and more cautious counseling.

Defer treatment when the skin is unstable

Postpone treatment in areas with active dermatitis, acne inflammation, infection, open wounds, or significant irritation. Treating inflamed skin increases the likelihood of additional cytokine-driven melanogenesis and prolonged discoloration.

Recent tanning or intense ultraviolet exposure should also prompt deferral until the skin has returned to its baseline color and the patient can reliably follow photoprotection measures.

Stabilize melasma or existing PIH first

Laser energy can worsen melasma or established PIH by creating additional inflammation. If pigmentary disease is active, stabilize it medically before considering fractional laser treatment and establish realistic expectations that laser therapy may not be the primary treatment.

Review medication and healing risks

Review topical and systemic medications, pregnancy or pregnancy planning, photosensitizing drugs, abnormal scarring history, and conditions that impair wound healing.

Tretinoin and hydroquinone require individualized prescribing. Avoid or modify these agents when contraindicated, poorly tolerated, or clinically inappropriate.

Prepare the Skin Before the Procedure

Use a pre-conditioning regimen

For appropriate patients, apply 4% hydroquinone and tretinoin for approximately 4–6 weeks before treatment to reduce melanocyte activity and improve control of pre-existing pigmentation.

Tretinoin should generally be stopped about 2 weeks before laser treatment, allowing treatment-related irritation to settle. Hydroquinone timing should follow the clinician’s protocol and the patient’s tolerance.

Prevent pre-treatment irritation

The objective is stable, non-irritated skin, not aggressive exfoliation. Reduce or stop other irritating products, including harsh acids, abrasive scrubs, and unnecessary active ingredients, before the procedure.

If the pre-treatment regimen causes erythema, burning, scaling, or dermatitis, postpone treatment until the barrier has recovered. Irritated skin is a higher-risk treatment target.

Establish strict photoprotection

Patients should use a broad-spectrum sunscreen with SPF 30 or higher, with protection against UVA and UVB; protection against visible light is particularly relevant for pigment-prone patients.

Photoprotection should begin before treatment and continue rigorously afterward. Hats, shade, and avoidance of intentional tanning are important because sunscreen alone may not prevent all pigment stimulation.

Perform a test spot when risk is elevated

Test spots are advisable for Fitzpatrick IV–VI patients, individuals with a history of PIH or melasma, and patients receiving a new device or treatment protocol.

Assess the test area for excessive erythema, prolonged inflammation, blistering, unexpected darkening, or delayed pigmentary change before treating a larger region. A test spot reduces uncertainty but does not eliminate risk.

Prepare the treatment surface correctly

Remove makeup, creams, sunscreen, and other topical residues completely before firing the device. Residual substances can alter energy delivery or contribute to focal epidermal heating.

Confirm that the device’s contact-cooling or cold-air system is functioning before treatment begins.

Use Conservative Laser Parameters

Reduce MTZ density and coverage

Lower the density of microscopic treatment zones (MTZs) and avoid confluent coverage. Reducing the number of treated zones limits cumulative inflammation and bulk heat accumulation within melanin-rich skin.

For higher-risk patients, use fewer passes and lower overall coverage rather than attempting to achieve a rapid result in one session.

Lower fluence and avoid excessive thermal accumulation

Use conservative fluence settings appropriate to the device, indication, and patient’s test-spot response. The goal is controlled microscopic coagulation, not maximal visible injury.

Energy should be adjusted together with density. A low density does not make an aggressive fluence automatically safe if the total thermal load remains excessive.

Use continuous epidermal cooling

Apply active cooling throughout treatment, such as chilled sapphire contact cooling or external cold-air cooling, according to the device protocol.

Cooling helps limit epidermal temperature and localize thermal injury. It should be verified before treatment and maintained consistently during laser passes.

Limit passes and allow adequate recovery

Avoid unnecessary overlapping passes, especially over areas with dense pigmentation or prior PIH. Treatment intervals may need to be extended, in some cases toward up to 2 months, to allow inflammation and pigmentary changes to resolve before the next session.

Do not schedule the next treatment solely because the minimum device interval has elapsed; reassess the patient’s skin response first.

Monitor and Manage the Post-Treatment Period

Reinforce immediate photoprotection

Patients should begin strict sun avoidance and broad-spectrum sunscreen use immediately after treatment, consistent with the device’s aftercare instructions.

Ultraviolet and visible-light exposure during the inflammatory period can intensify melanogenesis and convert transient erythema into persistent PIH.

Support the barrier without causing occlusion-related problems

Use gentle, non-comedogenic moisturizers and avoid unnecessary irritants. Heavy occlusive ointments may aggravate acne-prone patients, so a semi-occlusive or non-comedogenic approach is often preferable.

Patients should not pick, scrub, or prematurely remove flaking skin, because mechanical irritation can prolong inflammation.

Monitor for delayed pigment change

Follow-up should assess erythema duration, edema, crusting, acne flares, and the development of new or worsening hyperpigmentation. Darkening that persists or progressively worsens requires clinical review before further laser treatment.

Depigmenting therapy after treatment should be individualized. Non-steroidal, non-hydroquinone depigmenting products may be considered after the acute treatment reaction has settled, often within a clinician-defined window such as 7–21 days.

Understanding the Trade-offs

Lower settings may require more sessions

Reducing fluence, density, and passes lowers PIH risk but may reduce the visible improvement from each session. Patients should be counseled that safer treatment may mean more sessions and slower results.

Nonablative does not mean risk-free

Nonablative fractional devices preserve much of the stratum corneum and epidermis, generally reducing complications compared with ablative resurfacing. However, microscopic thermal injury still produces inflammation and can trigger PIH in susceptible skin.

Hydroquinone and tretinoin are not universally tolerated

Hydroquinone can cause irritation or, rarely, other adverse pigmentary reactions with inappropriate or prolonged use. Tretinoin commonly causes dryness and irritation, so neither should be continued automatically if the skin is inflamed.

Aggressive treatment is not a substitute for good selection

Increasing energy to compensate for low density, stacking passes, or treating unstable pigmentary disease can negate the safety benefit of a fractional approach.

The clinician should prioritize predictable healing over the maximum possible treatment intensity.

Making the Right Choice for Your Goal

Use the following framework when establishing a clinic protocol:

If your primary focus is PIH prevention: Require Fitzpatrick assessment, pigmentary history, stable non-inflamed skin, pre-conditioning when appropriate, test spots, conservative density and fluence, and continuous cooling.
If your primary focus is treating photodamage or rhytids: Select patients with mild-to-moderate disease and explain that multiple lower-intensity sessions may be safer than one aggressive treatment.
If your primary focus is treating melasma or existing PIH: Stabilize the pigmentary condition first, use strict visible-light and ultraviolet protection, and recognize that laser treatment may worsen rather than improve the condition.
If your primary focus is operational safety: Standardize documentation, test-spot assessment, device-specific parameter limits, post-treatment instructions, and follow-up before scheduling the next session.

For darker skin types, the most reliable PIH prevention strategy is disciplined patient selection combined with controlled thermal exposure and meticulous photoprotection.

Summary Table:

Key Aspect	Recommendation
Patient Selection	Fitzpatrick IV-VI, mild-to-moderate photodamage, stable skin
Pre-treatment	4% hydroquinone + tretinoin for 4-6 weeks; stop tretinoin 2 weeks before
Test Spot	Recommended for high-risk patients
Laser Parameters	Low density, low fluence, continuous cooling, minimal passes
Post-treatment	Strict sun protection, gentle skincare, monitor for pigment changes
Treatment Interval	May extend up to 2 months

Ready to enhance your clinic's laser safety and efficacy? At BELIS, we specialize in professional-grade aesthetic devices tailored for clinics and premium salons. Our advanced systems, including nonablative fractional lasers, are designed with advanced cooling and precise energy control to help you achieve optimal results while minimizing risks like PIH. Partner with us for cutting-edge technology, comprehensive training, and ongoing support. Contact our experts today to schedule a consultation and elevate your practice with BELIS.